About Remy Peptides — Dubai Research Peptide Supplier

Five public pages cover company identity, batch documentation, source rules, review workflow, and contact channels. Use them to verify any claim on the rest of the site.

Pre-launch, the founding team worked through the published literature on peptide pharmacology, HPLC analytical methods, and supplier-verification workflows. The operating rule that came out of that work still holds: primary sources only, batch documentation before any claim, and a editorial review on pages that carry scientific numbers.

The weak point in the UAE research peptide market was not demand; it was documentation. Supplier COAs often could not be independently traced, cold-chain handling was inconsistent, and purity claims on labels did not always match their supporting reports. If the supply chain could not be audited, the downstream research could not be trusted.

Supplier verification became part of the brand as a result, rather than a back-office step. The pages linked above are the same documents we use internally.

Due diligence focused on what could be audited: raw material sourcing, synthesis methodology, GMP status, sterility controls, validated HPLC and LC-MS workflows, and willingness to publish independent third-party reports through Janoshik Analytical rather than vendor-only documentation.

Batch RETP002 (Retatrutide 30mg Pen) was tested by Janoshik Analytical on 4 November 2025 at 99.262% HPLC. The Retatrutide 20mg Pen batch RET-20-C-2604-001 (99.841% HPLC, 23 April 2026) and the Retatrutide vial-line batch RET-20-V-2604-001 (99.741% HPLC, 22 April 2026) are also in the COA Library. The 20mg pen batch is the highest published HPLC purity Retatrutide pen in the catalogue.

• Janoshik-verified batches — our published Retatrutide batches are independently tested by Janoshik Analytical. Retatrutide 30mg Pen, batch RETP002: 99.262% HPLC (4 November 2025). Retatrutide 20mg Pen, batch RET-20-C-2604-001: 99.841% HPLC at 22.51 mg/mL measured concentration (23 April 2026). Retatrutide vial line, batch RET-20-V-2604-001: 99.741% HPLC, 20.92 mg assay, heavy metals not detected, TFA not detected (22 April 2026). Full reports live in the COA Library; the Peptide COA Guide explains how to read them.
• Documented or not published — brand facts, editorial policy, research standards, and contact verification are on dedicated pages. Claims that can’t be traced to a primary source do not ship.
• Single manufacturing partner — one cGMP-compliant production facility. No brokers, no anonymous resellers, no repackaged material.
• 2–8°C cold chain — temperature-controlled from storage to handoff. Same-day delivery inside Dubai; courier across the GCC.
• In-vitro research only — UAE MoHAP Circular 17/2022 is the baseline compliance reference. No human or veterinary dosing, diagnostic, or treatment claims.